RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides

Status Completed

Clinical Trial Summary

The purpose of this study is to compare a 2 immunosuppressant regimen for the treatment of relapsing or refractory necrotizing antineutrophil cytoplasmic antibody (ANCA) associated vasculitides.

Clinical Trial Description

The aim of this study is to compare the efficacy of rituximab versus infliximab in relapsing or refractory forms of ANCA+ vasculitides (Microscopic Polyangiitis, Wegener's granulomatosis and Churg-Strauss syndrome). ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00307593
Study type	Interventional
Source	Assistance Publique - Hôpitaux de Paris
Contact
Status	Completed
Phase	N/A
Start date	May 2004
Completion date	June 2007

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT01729624` - PRO Development for ANCA Associated Vasculitis	N/A
Terminated	`NCT02474888` - Pharmacokinetic Study of Rituximab Induction Regimen in ANCA-associated Vasculitis
Active, not recruiting	`NCT02198248` - Low-dose Glucocorticoid Vasculitis Induction Study	Phase 4
Completed	`NCT02190916` - Vasculitis Illness Perception (VIP) Study	N/A
Recruiting	`NCT01241305` - One-Time DNA Study for Vasculitis
Completed	`NCT00748644` - Efficacy Study of Two Treatments in the Remission of Vasculitis	Phase 3
Recruiting	`NCT02967068` - VCRC Tissue Repository
Completed	`NCT01731561` - Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis	Phase 3
Not yet recruiting	`NCT06350110` - Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)	Phase 1/Phase 2
Completed	`NCT02190942` - VCRC Patient Contact Registry Patient-Reported Data Validation Study
Not yet recruiting	`NCT02126098` - Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis	N/A
Terminated	`NCT01586858` - Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study	N/A
Completed	`NCT02190929` - Educational Needs of Patients With Systemic Vasculitis	N/A
Terminated	`NCT01408836` - Plasma Exchange for Renal Vasculitis	Phase 2/Phase 3
Terminated	`NCT05376319` - PR3-AAV Resilient Remission or PRRR	Phase 2
Completed	`NCT02476292` - Impact of Vasculitis on Employment and Income	N/A
Completed	`NCT02169219` - Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis	Phase 4
Completed	`NCT01613599` - An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
Active, not recruiting	`NCT05716334` - Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator
Completed	`NCT00307671` - Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years	Phase 4